celecoxib has been researched along with lactic acid in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Clyman, RI; Kajino, H; Roman, C | 1 |
| Ayalasomayajula, SP; Kompella, UB | 1 |
| Amrite, AC; Ayalasomayajula, SP; Cheruvu, NP; Kompella, UB | 1 |
| Donnelly, RF; Marouf, W; McCarron, PA | 1 |
| Amrite, AC; Cheruvu, NP; Kompella, UB | 1 |
| Donnelly, RF; Marouf, WM; McCarron, PA; Scott, C | 1 |
| Bohr, A; Dyas, M; Edirisinghe, M; Kristensen, J; Stride, E | 2 |
| Jeong, YI; Jin, SG; Jung, S; Jung, TY; Kang, SS; Kim, IY; Kim, TH; Moon, KS; Pei, J | 1 |
| Bjerregaard, S; Bohr, A; Foged, C; Maltesen, MJ; Rantanen, J; Wan, F; Yang, M | 1 |
| Abd-Elgawad, AE; Ibrahim, MM; Jablonski, MM; Soliman, OA | 1 |
| Allhenn, D; Béduneau, A; Lamprecht, A; Neumann, D; Pellequer, Y | 1 |
| Dhanda, DS; Kompella, UB; Mirvish, SS; Tyagi, P | 1 |
| Cannavà, C; Cardile, V; Cilurzo, F; Giannone, I; Puglisi, G; Stancanelli, R; Tommasini, S; Ventura, CA | 1 |
| Barcia, E; Fernández-Carballido, A; García-García, L; Marcianes, P; Negro, S; Slowing, K; Vera, M | 1 |
| Beekhuizen, M; Creemers, LB; Dhert, WJ; Janstål, MK; Licht, R; Öner, FC; Schumann, D; van Dijk, M; van Rijen, M; Yang, HY | 1 |
| Cooper, DL; Harirforoosh, S | 1 |
| Baldursdottír, S; Bohr, A; Dyas, M; Edirisinghe, M; Kristensen, J; Stride, E; Wan, F; Yang, M | 1 |
| Allémann, E; Černý, R; Guénée, L; Jordan, O; Salgado, C | 1 |
| Grizić, D; Lamprecht, A | 1 |
| Emami, J; Kazemi, M; Rezazadeh, M; Ziaei, E | 1 |
| Huang, J; Li, C; Lin, J; Tang, B; Wu, J; Xiao, H | 1 |
23 other study(ies) available for celecoxib and lactic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Renal effects of cyclooxygenase-2 inhibition in fetal lambs.
Topics: Animals; Arteries; Body Water; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Hydrogen-Ion Concentration; Isoenzymes; Kidney; Lactic Acid; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sheep; Sulfonamides; Urine | 2002 |
Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.
Topics: Aldehydes; Animals; Celecoxib; Conjunctiva; Cyclooxygenase Inhibitors; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Glutathione; Glutathione Disulfide; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Oxidative Stress; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazoles; Rats; Rats, Sprague-Dawley; Retina; Sulfonamides; Thiobarbituric Acid Reactive Substances; Time Factors | 2005 |
Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.
Topics: Animals; Blood-Retinal Barrier; Capillary Permeability; Celecoxib; Cell Culture Techniques; Cyclooxygenase Inhibitors; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dinoprostone; Drug Carriers; Humans; Injections; Lactic Acid; Male; Microspheres; Pigment Epithelium of Eye; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Vascular Endothelial Growth Factor A | 2006 |
Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure.
Topics: Acetone; Biocompatible Materials; Calorimetry, Differential Scanning; Celecoxib; Cyclooxygenase Inhibitors; Delayed-Action Preparations; Diffusion; Drug Compounding; Lactic Acid; Magnesium Chloride; Methylene Chloride; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazoles; Solvents; Sonication; Sulfonamides; Surface Properties; Viscosity | 2006 |
Effect of eye pigmentation on transscleral drug delivery.
Topics: Animals; Area Under Curve; Biological Availability; Celecoxib; Choroid; Cyclooxygenase 2 Inhibitors; Drug Carriers; Eye Color; Lactic Acid; Male; Melanins; Pigment Epithelium of Eye; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazoles; Rats; Rats, Inbred BN; Rats, Sprague-Dawley; Retina; Sclera; Sulfonamides; Vitreous Body | 2008 |
Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biocompatible Materials; Cattle; Celecoxib; Drug Carriers; Drug Delivery Systems; Drug Stability; Humans; Lactic Acid; Ligands; Materials Testing; Molecular Structure; Molecular Weight; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazoles; Sulfonamides; Surface Properties | 2008 |
Preparation of microspheres containing low solubility drug compound by electrohydrodynamic spraying.
Topics: Calorimetry, Differential Scanning; Celecoxib; Cyclooxygenase 2 Inhibitors; Diffusion; Drug Compounding; Drug Delivery Systems; Electrochemical Techniques; Hydrodynamics; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Porosity; Pyrazoles; Solubility; Sulfonamides; Surface Properties; Temperature; Transition Temperature | 2011 |
Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.
Topics: Acetone; Animals; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Drug Carriers; Drug Stability; Glioma; Humans; Lactic Acid; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Powder Diffraction; Pyrazoles; Rats; Solvents; Sulfonamides | 2011 |
Release profile and characteristics of electrosprayed particles for oral delivery of a practically insoluble drug.
Topics: Celecoxib; Drug Delivery Systems; Humans; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazoles; Sulfonamides; X-Ray Diffraction | 2012 |
Critical solvent properties affecting the particle formation process and characteristics of celecoxib-loaded plga microparticles via spray-drying.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Desiccation; Drug Carriers; Lactic Acid; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazoles; Solvents; Sulfonamides; Surface Properties | 2013 |
Nanoparticle-based topical ophthalmic formulations for sustained celecoxib release.
Topics: Administration, Ophthalmic; Celecoxib; Cell Survival; Cyclooxygenase 2 Inhibitors; Delayed-Action Preparations; HEK293 Cells; Humans; Lactic Acid; Nanoparticles; Particle Size; Polyesters; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazoles; Sulfonamides; Viscosity | 2013 |
A "drug cocktail" delivered by microspheres for the local treatment of rat glioblastoma.
Topics: Acridines; Animals; Antineoplastic Agents, Phytogenic; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Carriers; Etoposide; Glioblastoma; Lactic Acid; Male; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides; Tetrahydroisoquinolines | 2013 |
Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzo(a)pyrene; Bronchoalveolar Lavage Fluid; Carboplatin; Celecoxib; Cell Count; Collagen; Delayed-Action Preparations; Female; L-Lactate Dehydrogenase; Lactic Acid; Lung Neoplasms; Mice; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Porosity; Pulmonary Fibrosis; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2013 |
Celecoxib-loaded PLGA/cyclodextrin microspheres: characterization and evaluation of anti-inflammatory activity on human chondrocyte cultures.
Topics: Anti-Inflammatory Agents; Calorimetry, Differential Scanning; Celecoxib; Cells, Cultured; Chondrocytes; Circular Dichroism; Cyclodextrins; Diclofenac; Diffusion; Humans; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazoles; Sulfonamides | 2013 |
New celecoxib multiparticulate systems to improve glioblastoma treatment.
Topics: Animals; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Delayed-Action Preparations; Glioblastoma; Humans; Inflammation; Lactic Acid; Male; Microspheres; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polysorbates; Pyrazoles; Rats, Wistar; Sulfonamides | 2014 |
Applicability of a newly developed bioassay for determining bioactivity of anti-inflammatory compounds in release studies--celecoxib and triamcinolone acetonide released from novel PLGA-based microspheres.
Topics: Anti-Inflammatory Agents; Biological Assay; Celecoxib; Cells, Cultured; Chondrocytes; Drug Carriers; Humans; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazoles; Sulfonamides; Triamcinolone Acetonide | 2015 |
Effect of formulation variables on preparation of celecoxib loaded polylactide-co-glycolide nanoparticles.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biocompatible Materials; Biological Availability; Celecoxib; Chemistry, Pharmaceutical; Lactic Acid; Lecithins; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazoles; Sulfonamides | 2014 |
Pharmaceutical microparticle engineering with electrospraying: the role of mixed solvent systems in particle formation and characteristics.
Topics: Capsules; Celecoxib; Complex Mixtures; Diffusion; Drug Compounding; Electroplating; Lactic Acid; Materials Testing; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazoles; Solvents; Sulfonamides; Surface Properties | 2015 |
Nano wet milled celecoxib extended release microparticles for local management of chronic inflammation.
Topics: Celecoxib; Drug Liberation; Humans; Inflammation; Lactic Acid; Osteoarthritis; Particle Size | 2020 |
Process parameters of microsphere preparation based on propylene carbonate emulsion-precursors.
Topics: Calorimetry, Differential Scanning; Celecoxib; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Drug Liberation; Emulsions; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Particle Size; Polyglycolic Acid; Polymers; Polypropylenes; Solubility; Solvents; Surface Properties; Viscosity | 2021 |
Pulmonary Delivery of Docetaxel and Celecoxib by PLGA Porous Microparticles for Their Synergistic Effects Against Lung Cancer.
Topics: Celecoxib; Docetaxel; Drug Carriers; Humans; Lactic Acid; Lung Neoplasms; Particle Size; Porosity | 2022 |
Poly(lactic acid-co-glycolic acid)-based celecoxib extended-release microspheres for the local treatment of traumatic heterotopic ossification.
Topics: Animals; Celecoxib; Glycolates; Lactic Acid; Microspheres; Ossification, Heterotopic; Osteogenesis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley | 2022 |